Weekly Meeting with Dr. Hannah

Presenter: Hasan Shaikh

Quantitative Imaging Research and

Artificial Intelligence Lab (QIRAIL)

Oncode Accelerator

What & Why

Dutch public-private consortium to accelerate cancer-therapy R&D. It tackles high cost and long timelines.

Mission

To put real patients at the core of research. Promising treatments reach trials faster with less risk.

Platforms & Therapy Workstreams

1. Platforms

₽ Patient Cohorts	∫ Organoids	Artificial Intelligence
Well-annotated clinical/genomic data for target validation & trial design.	Patient-derived "mini-tumors" for high-fidelity drug screening.	ML tools to predict efficacy, toxicity & ideal patient subgroups.

2. Workstream

Small Molecules	<u></u> Biologics		Therapeutic Vaccines
Kinase inhibitors, oral drugs.	Antibodies, ADCs, checkpoint inhibitors.	CAR-T, TIL, gene-edited cells.	Neoantigen & immune-training vaccines.

To make optimal use of our preclinical development infrastructure, we built four preclinical development pipelines, so called Workstreams, representing the development of the four most prominent types of cancer therapies.

Oncode Accelerator Demo Project Timeline

Rolling Calls End

Final deadline for project applications



Contracts Begin

Formal agreements signed for approved projects



Project Kick-off

Begin project under Oncode management



Advisory Board Review

Receive feedback and go/no-go decision



Proposal Co-development

Collaborate with leads to refine project proposal



Intake Form Submission

Send form to demonstrators@oncodeaccelerator.nl



Q2 2025 None

None

None

3-4 h

Benefits of Collaboration



Shared Resources

Access data, models, and regulatory expertise.



Lower Risk & Cost

Co-funding reduces financial burden and risk.



Faster Screening

Patient-centric screening accelerates decisionmaking process.